Department of Urology, Kurume University School of Medicine, Kurume, Japan
Department of Urology, Kurume University School of Medicine, Kurume, Japan.
Anticancer Res. 2020 Mar;40(3):1739-1745. doi: 10.21873/anticanres.14127.
BACKGROUND/AIM: The present study examined the impact of systemic inflammatory markers including C-reactive protein (CRP)/Albumin (Alb) and neutrophil lymphocyte ratio (NLR)/Alb on the prognosis of patients treated with first line molecular targeted therapy for advanced RCC.
A total of 131 patients with advanced RCC treated with molecular targeted therapy as first line treatment from May 2008 to April 2019 were retrospectively analyzed.
High CRP, high NLR, low Alb and high CRP/Alb showed significantly worse progression-free survival (PFS) and overall survival (OS) than low CRP, low NLR, high Alb, low CRP/Alb and low NLR/Alb, respectively. In multivariate analyses, prior nephrectomy (p=0.0321) and NLR/Alb ratio (p=0.0327) were independent prognostic factors for PFS. Furthermore, prior nephrectomy (p=0.0013) and CRP/Alb ratio (p=0.0020) were independent prognostic factors for OS.
CRP/Alb and NLR/Alb ratios are useful and independent prognostic biomarkers in patients with advanced RCC treated with molecular targeted therapy.
背景/目的：本研究旨在探讨包括 C 反应蛋白（CRP）/白蛋白（Alb）和中性粒细胞与淋巴细胞比值（NLR）/Alb 在内的系统性炎症标志物对接受一线分子靶向治疗的晚期 RCC 患者预后的影响。
回顾性分析了 2008 年 5 月至 2019 年 4 月期间接受分子靶向治疗作为一线治疗的 131 例晚期 RCC 患者。
高 CRP、高 NLR、低 Alb 和高 CRP/Alb 组的无进展生存期（PFS）和总生存期（OS）明显差于低 CRP、低 NLR、高 Alb、低 CRP/Alb 和低 NLR/Alb 组。多因素分析显示，既往肾切除术（p=0.0321）和 NLR/Alb 比值（p=0.0327）是 PFS 的独立预后因素。此外，既往肾切除术（p=0.0013）和 CRP/Alb 比值（p=0.0020）是 OS 的独立预后因素。
CRP/Alb 和 NLR/Alb 比值是接受分子靶向治疗的晚期 RCC 患者有用的独立预后生物标志物。
